Robert J. Kurma, Maria Luisa Carcangiu, C. Simon Herrington, et al. WHO Classification of Tumours of Female Reproductive Organs [M]. Lyon: IARCC, 2014: 129-130.
Damast S, Higgins SA, Ratner E, et al. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma [J]. J Contemp Brachytherapy, 2015, 7(1):35-40.
Zhu L, Lopez S, Bellone S, et al. Dacomitinib (PF-00299804), a second -generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro [J]. Tumour Biol, 2015, 11.
Schwab CL, Bellone S, English DP, et al. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo [J]. Br J Cancer, 2014, 111(9):1750-1756.
Schwab CL, English DP, Roque DM1, et al. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo [J]. Gynecol Oncol, 2014, 135(1):142-8.